With 1 ETF traded in the U.S. markets, LifeSci Biotechnology Clinical Trials Index ETF gathers total assets under management of $12.50M. The average expense ratio is 0.79%. LifeSci Biotechnology Clinical Trials Index ETF can be found in the following asset class:
Looking for the perfect partner for the world’s largest ETF.
New small/midcap fund will target stocks exhibiting steady dividend growth.
The segment is delivering some impressive gains after a bout of investor doubt.
These 10 ETFs dropped by 30% or more despite a rally in the broad market.
In this series, we look under the hood of some of the ETF portfolios in the market today.
New funds focus on environmental, social and governance standards for investing in emerging and developed markets.
These three popular slices of the ETF universe are faring poorly this year.
It's still early in the year, but a number of ETFs have already lost 25-50% of their value in 2016.
If a wild ride is in store for U.S. equity investors, here are some thoughts to consider.